Document is current
Any future updates will be listed below
-
Authors
Sadeghi, Elham
Schulman, Anne
Vupparaboina, Sharat Chandra
Singh, Sumit Randhir
Hasan, Nasiq
Bollepalli, Sandeep Chandra https://orcid.org/0000-0002-9971-9335
Vupparaboina, Kiran Kumar
Sahel, Jose Alain https://orcid.org/0000-0002-4831-1153
Eller, Andrew W. https://orcid.org/0000-0002-6472-5460
Chhablani, Jay https://orcid.org/0000-0003-1772-3558
- License Information
-
More Information
Article History
Received: 25 December 2024
Revised: 29 April 2025
Accepted: 7 May 2025
First Online: 15 May 2025
Competing interests
: JAS: Avista Therapeutics, Tenpoint, Code C (Consultant/Contractor), Clinical Trials: Gensight, SparingVision, Meira, Code F (Financial Support), Netramind Innovations, Gensight, Sparing Vision, Avista, Tenpoint, Prophesee, Chronolife, Tilak Healthcare, SharpEye, Cilensee, Vegavect, Code O (Owner), Allotopic Expression, Rod-derived Cone Viability Factor and related patents., Code P (Patent), Patent Royalties, Gensight, Code R (Recipient), Observer: Gensight, SparingVision, Avista, Vegavect. President: Fondation Voir et Entendre, Paris; President: StreetLab, Paris., Code S (non-remunerative); JC: Netramind Innovations, Code O (Owner). KKV: Netramind Innovations, Code O (Owner). SCB: Netramind Innovations, Code O (Owner).
